Clinical Trials on Hepatitits C

Total 4630 results

Hoffmann-La Roche
Santaris Pharma A/S

Completed

Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin

Chronic Hepatitis C

Puerto Rico
ANRS, Emerging Infectious Diseases
Institut Pasteur

Withdrawn

Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (ViZIR)

Chronic Hepatitis C

Egypt
Norte Study Group
Merck Sharp & Dohme LLC

Unknown

Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)

Chronic Hepatitis C
Beijing Ditan Hospital

Completed

The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C

Chronic Hepatitis C

China
Debiopharm International SA
Parexel

Completed

A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

Chronic Hepatitis C

Spain, Belgium, Germany, Romania, France, Poland, Italy
Presidio Pharmaceuticals, Inc.
Boehringer Ingelheim

Completed

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Chronic Hepatitis C

United States
Pontificia Universidad Catolica de Chile

Unknown

Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection (EZE-1)

Chronic Hepatitis C

Chile
Bristol-Myers Squibb

Completed

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Chronic Hepatitis C

France, United States, Puerto Rico
Merck Sharp & Dohme LLC

Withdrawn

Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)

Chronic Hepatitis C
Can-Fite BioPharma

Completed

A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1

Chronic Hepatitis C

Israel
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C

Chronic Hepatitis C

Taiwan
Duke University

Completed

Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C

Chronic Hepatitis C

United States
Third Affiliated Hospital, Sun Yat-Sen University

Completed

Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6

Chronic Hepatitis C

China
Scynexis, Inc.

Completed

Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

Chronic Hepatitis C

United States
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

Chronic Hepatitis C

Japan
Institut National de la Santé Et de la Recherche...

Terminated

A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients

Hepatitis C

France
EMD Serono
Merck Pte. Ltd., Singapore

Completed

A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects

Hepatitis C
National Institute of Diabetes and Digestive and...

Completed

S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C

Chronic Hepatitis C

United States
MinaPharm Pharmaceuticals

Unknown

Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C (HAPIC)

Chronic Hepatitis C

Egypt
Bausch Health Americas, Inc.

Completed

Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy

Chronic Hepatitis C
The Immunobiological Technology Institute (Bio-Manguinhos)...
Hospital de Clinicas de Porto Alegre

Unknown

BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C (BIP48II/III)

Chronic Hepatitis C

Brazil
Asan Medical Center
Samsung Medical Center; Seoul St. Mary's Hospital; Korea University Guro Hospital and other collaborators

Completed

Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C

Chronic Hepatitis C

Korea, Republic of
Hospices Civils de Lyon

Unknown

RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin (RIBAJUSTE)

Chronic Hepatitis C

France
ChronTech Pharma AB
Inovio Pharmaceuticals

Unknown

CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects

Chronic Hepatitis C

Sweden
Chugai Pharmaceutical

Completed

Trial of Pegasys® in Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
Anza Therapeutics, Inc.

Terminated

Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

Chronic Hepatitis C

United States
Kaohsiung Medical University Chung-Ho Memorial...

Completed

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients

Chronic Hepatitis C | Genotype

Taiwan
University Hospital, Limoges
Hoffmann-La Roche

Completed

Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM (CINAM)

Chronic Hepatitis C

France
French National Agency for Research on AIDS and...
Hoffmann-La Roche

Completed

Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)

Chronic Hepatitis C

Egypt
Foundation for Liver Research
Kyowa Kirin Co., Ltd.

Completed

Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection

Chronic Hepatitis C

Netherlands
Weill Medical College of Cornell University
Schering-Plough

Completed

Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects

Chronic Hepatitis C
Hopital A Michallon
Central Hospital, Nancy, France; University Hospital, Grenoble

Terminated

Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C

Chronic Hepatitis C

France
UMC Utrecht

Completed

Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients

Chronic Hepatitis C

Netherlands
Gilead Sciences

Terminated

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Hepatitis C Virus Infection

France, Spain, United States, Australia, Canada, Germany, United Kingdom, Italy, New Zealand, Puerto Rico
Muhammad Radzi Abu Hassan

Recruiting

8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

Hepatitis C

Malaysia
University of Florida
Patient-Centered Outcomes Research Institute; Merck Sharp & Dohme LLC; AbbVie

Completed

Study of Oral Treatments for Hepatitis C (PRIORITIZE)

Chronic Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035) (C-WORTHy)

Hepatitis C
Changi General Hospital
National University Hospital, Singapore

Completed

Epidemiology of Chronic Hepatitis C and Disease Modelling (EPIC)

Hepatitis C

Singapore
Merck Sharp & Dohme LLC

Completed

Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)

Chronic Hepatitis C
Assiut University

Unknown

Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs

Hepatitis C
Janssen R&D Ireland

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients (RESTORE)

Hepatitis C

France, Belgium
Microbio Co Ltd

Unknown

A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients

Chronic Hepatitis C

Taiwan
Association HGE CHU Bordeaux Sud
University Hospital, Bordeaux

Completed

Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir (GENUPI)

Chronic Hepatitis C

France
Memorial Sloan Kettering Cancer Center

Completed

SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study

Hepatitis C

United States
Bristol-Myers Squibb

Completed

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Hepatitis C

United States, Australia, Canada, France, Puerto Rico
Bristol-Myers Squibb
Pharmasset

Completed

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

Chronic Hepatitis C

United States, Puerto Rico
Biocad

Completed

Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C

Hepatitis | Hepatitis C

Russian Federation
Janssen R&D Ireland
Gilead Sciences

Completed

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients (COSMOS)

Hepatitis C

United States, Puerto Rico

3

Subscribe